Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 11Osteoporosis 5Prostatic Neoplasms 4Neoplasms 4Multiple Myeloma 2Unspecified Childhood Solid Tumor, Protocol Specific 1Testicular Neoplasms 1Smoldering Multiple Myeloma 1Regional Osteoporosis as a Result of Chemotherapy 1Recurrence 1Polycystic Ovary Syndrome 1Paraganglioma, Extra-Adrenal 1Pain 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Metabolic Syndrome 1Menstruation Disturbances 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lymphedema 1Leukemia 1Hodgkin Disease 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Depression 1Cicatrix 1Cardiovascular Diseases 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrence × Absorptiometry, Photon × Clear all
NCT00401011 2018-02-23

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

AEterna Zentaris

Phase 1/2 Completed
84 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡